The Oncotype DX^® test plays a key role in a current clinical trial, the Trial Assigning IndividuaLized Options for Treatment (Rx), known as TAILORx. Participants will be divided into different treatment groups depending on their Recurrence Score^® results.

Patients with Recurrence Score results less than 11, who are at low risk for recurrence and for whom chemotherapy is expected to provide little benefit, will receive hormone therapy alone. Patients with Recurrence Score results greater than 25, who are at higher risk for recurrence and for whom chemotherapy is expected to provide substantial benefit, will receive hormone therapy and chemotherapy. Patients with Recurrence Score results between 11 and 25, whose risk for recurrence is moderate and for whom the benefit of chemotherapy is unclear, will be randomized to treatment with hormone therapy plus chemotherapy versus hormone therapy alone.

The primary objective of the trial is to determine whether hormonal therapy alone offers no less benefit than chemotherapy plus hormonal therapy in women whose Recurrence Score results range from 11 to 25. Participants in the trial are not financially liable for the cost of the Oncotype DX test.

If you have just been diagnosed with early-stage breast cancer, you and your physician may want to talk about whether this clinical trial could be right for you. For more information on TAILORx, please go to http://www.genomichealth.com/oncotype/tailorx/default.aspx.